News

2 Top Dividend Stocks to Buy on the Dip

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...
MedPage Today21h

First, the Dogs Died; In-Office Diagnostic Errors; Ovarian Cancer Paradigm Shift?

Schrödinger announced it will discontinue clinical development of the CDC7 inhibitor SGR-2921 for acute myeloid leukemia (AML) and myelodysplastic syndromes following two patient deaths in an ...

RFK Jr.’s mRNA hostility could hurt more than just vaccines

The Nobel Prize-winning technology underpinning COVID-19 vaccines is also fueling a host of biotechs developing treatments ...

AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs

AstraZeneca expects continued growth of its oncology medicines in the second half, particularly Tagrisso, Enhertu, and ...
BioPharma Dive23h

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.